Firms Sift Eye Study Data For Benefit From Lutein And Zeaxanthin
This article was originally published in The Tan Sheet
Executive Summary
After the Age-Related Eye Disease Study found lutein, zeaxanthin and omega-3s do not slow age-related macular degeneration, supplement firms revisit the data and find lutein and zeaxanthin could slow the disease in deficient populations.
You may also be interested in...
Bausch + Lomb Social Media Campaign On Living With AMD Suggests AREDS Supplements
“What Sight Inspires You” campaign features stories and sights from B+L’s SightMatters online resource for people living with AMD, along with educational content on the condition including developing plans to help reduce risk of progression.
US Supplement Industry Sees Encouragement From Federal Research Agency, Caution From Regulator
FDA launches initiative to advise health care professionals and consumers about potential benefits and risks associated with supplements; NIH announces latest strong results from ongoing AREDS study; and Walmart recalls drug-spiked supplement agency initially identified as adulterated in January.
Wellness Market News: Abbott Nutrition Q3 Up 1.6%, Easier-To-Swallow PreserVision AREDS, More
Ensure, Glucerna brands boost Abbott Nutrition adult product third-quarter sales 3.9% on reported basis to $830m; Baush + Lomb relaunches PreserVision AREDS 2 Formula soft gels with easier-to-swallow option; Hum Nutrition Mighty Night supplement boosts skin cell renewal during sleep; and NOW Health Group acquires family-owned SuperNutrition.